LENZ
LENZ Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$283.76M
P/E Ratio
—
EPS
$-2.85
Beta
2.29
52W High
$50.40
52W Low
$8.25
50-Day MA
$10.77
200-Day MA
$24.87
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About LENZ Therapeutics Inc
LENZ Therapeutics Inc is a pioneering biopharmaceutical company focused on delivering innovative therapies for neurological disorders, targeting critical unmet needs in the central nervous system (CNS). The company leverages cutting-edge advancements in drug formulation and delivery, underpinned by a strong pipeline of proprietary technologies aimed at improving patient outcomes. With strategic collaborations and a dedication to comprehensive clinical research, LENZ is well-positioned to establish itself as a significant contributor to the biopharmaceutical sector, poised for substantial growth in the dynamic healthcare market.
Fundamentals
| Revenue (TTM) | $19.09M |
| Gross Profit (TTM) | $18.67M |
| EBITDA | $-90.85M |
| Operating Margin | -2422.00% |
| Return on Equity | -33.60% |
| Return on Assets | -21.90% |
| Revenue/Share (TTM) | $0.66 |
| Book Value | $9.07 |
| Price-to-Book | 1.00 |
| Price-to-Sales (TTM) | 14.87 |
| EV/Revenue | 0.759 |
| EV/EBITDA | -7.99 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $31.35M |
| Float | $18.48M |
| % Insiders | 2.65% |
| % Institutions | 121.68% |
Historical Volatility
HV 10-Day
68.10%
HV 20-Day
58.34%
HV 30-Day
88.69%
HV 60-Day
74.69%
HV Rank
67.1%
Volatility is currently contracting
Analyst Ratings
Consensus ($39.57 target)
1
Strong Buy6
BuyData last updated: 4/30/2026